Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Collections
>
China Healthcare
COLLECTION
China Healthcare
Growing pains
Follow
Share
2.9k
Insights
1.2m
Views
14
Followers
Follow
Share
Regions
Sectors
Verticals
More Filters
Focused
Top Picks Only
Recent
bullish
•
Shanghai Henlius Biotech
•
23 Dec 2024 12:51
Henlius (2696 HK): Circ Out. 22nd Jan H-Class Meeting
Currently at a 2.9% gross spread with expected payment around the third week of Feb. I'd pay up to HK$24.10/share for a 15% annualised spread.
David Blennerhassett
Follow
30 Views
Share
bullish
•
Shanghai Henlius Biotech
•
23 Dec 2024 08:20
Shanghai Henlius Biotech (2696.HK) Privatization Update- Looks Like "An Agreement" Has Been Reached?
All Pre-Conditions have been fulfilled and the document is out. The Offeror needs to meet the obligations, which means that Fosun needs to solve...
Xinyao (Criss) Wang
Follow
551 Views
Share
bullish
•
Shanghai Henlius Biotech
•
22 Dec 2024 22:02
Henlius (2696 HK): Interesting Shareholder Movements with the Vote on 22 January
Key shareholders will be supportive, and this is a done deal. At the last close, the gross/annualised spread for a 15 February payment was 2.9%...
Arun George
Follow
232 Views
Share
bullish
•
Thematic (Sector/Industry)
•
22 Dec 2024 07:30
APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin
Mesoblast got FDA approval for its first drug, while Betta Pharma, Celltrion, and Lupin also received some major FDA approvals. Pharma companies...
Tina Banerjee
Follow
234 Views
Share
bullish
•
Hansoh Pharmaceutical Group
•
20 Dec 2024 22:22
•
Broker
Hansoh Pharma (3692 HK) - Oral GLP-1 Candidate Accomplished Transaction with MSD
Hansoh out-licensed oral GLP-1 drug to MSD. Hansoh has granted MSD a global exclusive license for HS-10535, a preclinical stage oral small molecule...
CMB International
Follow
363 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x